{
    "clinical_study": {
        "@rank": "114399", 
        "acronym": "ACROSCREEN", 
        "arm_group": {
            "arm_group_label": "Acromegaly patients"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the protocol is to define percentage of patients with acromegaly in\n      relation to the total number of screened patients with confirmed clinically significant set\n      of associated somatic disorders with the help of laboratory (Insulin-like Growth Factor I,\n      Growth Hormone, Oral Glucose-Tolerance Test [IGF-1, GH, OGTT]) and instrumental examination\n      methods (Magnetic Resonance Imaging [MRI])."
        }, 
        "brief_title": "Programme of Acromegaly Screening in Patients With Associated Somatic Disorders", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acromegaly", 
        "condition_browse": {
            "mesh_term": "Acromegaly"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women aged 18 years and above with associated somatic disorders observed at\n             the Moscow Endocrinology dispensary or Endocrinology Hospital at First Moscow State\n             Medical University\n\n          -  Patients who signed the Informed Consent Form for participation in the survey before\n             collection of any information.\n\n        Exclusion Criteria:\n\n          -  Patient already diagnosed with acromegaly\n\n          -  Patient's refusal to participate in the survey."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with associated acromegaly somatic disorders, who are observed at the Moscow\n        Board of Health Endocrinology dispensary and Endocrinology Hospital at First Moscow State\n        Medical University"
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020967", 
            "org_study_id": "A-38-52030-280"
        }, 
        "intervention": {
            "arm_group_label": "Acromegaly patients", 
            "description": "This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.", 
            "intervention_name": "Non-interventional cross-sectional survey", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119034"
                    }, 
                    "name": "Moscow Board of Health Endocrinology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119435"
                    }, 
                    "name": "Endocrinology Hospital at First Moscow State Medical University"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Programme of Acromegaly Screening in Patients With Associated Somatic Disorders, Who Are Observed at the Moscow Board of Health Endocrinology Dispensary and Endocrinology Hospital at First Moscow State Medical University for the Purpose of Early Identification of the Disease.", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Elena Poznyakova, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percentage of patients with acromegaly in relation to the total amount of screened patients with confirmed clinically significant set of associated somatic disorders with the help of laboratory (IGF-1, GH, OGTT) and instrumental examination methods (MRI).", 
            "measure": "Percentage of patients with acromegaly", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020967"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients diagnosed with acromegaly with the help of laboratory (IGF-1, GH, OGTT) and instrumental examination methods (MRI)", 
                "measure": "Number of patients diagnosed with acromegaly", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Demographic data of patients with confirmed clinically significant set of associated somatic disorders (age, sex);", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Percentage of patients with microadenomas, registered during MRI examination", 
                "measure": "Percentage of patients with microadenomas", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Percentage of patients with macroadenomas, registered during MRI examination", 
                "measure": "Percentage of patients with macroadenomas", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}